| Literature DB >> 34545711 |
Mengmeng Song1,2, Qi Zhang1,2, Meng Tang1,2, Xi Zhang1,2, Guotian Ruan1,2, Xiaowei Zhang1,2, Kangping Zhang1,2, Yizhong Ge1,2,3, Ming Yang1,2, Qinqin Li1,2,4, Xiangrui Li1,2, Xiaoyue Liu1,2,5, Wei Li6, Minghua Cong7, Kunhua Wang8, Chunhua Song9, Hanping Shi1,2.
Abstract
BACKGROUNDS: Hand grip strength (HGS) is one of diagnose criteria factors of sarcopenia and is associated with the survival of patients with cancer. However, few studies have addressed the association of HGS and 1 year mortality of patients with cancer cachexia.Entities:
Keywords: Cancer cachexia; Hand grip strength; Mortality; Prognosis
Mesh:
Year: 2021 PMID: 34545711 PMCID: PMC8718026 DOI: 10.1002/jcsm.12778
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Figure 1Flow chart. INSCOC, Investigation on Nutrition Status and its Clinical Outcome of Common Cancers; HGS, hand grip strength.
Baseline characteristics of the study population.
| Variables | All cancer | Non‐cachexia | Cachexia |
| High HGS | Low HGS |
|
|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||
| Age, mean (SD) | 56.74 (12.03) | 56.54 (11.82) | 57.75 (12.97) | 0.001 | 56.34 (12.35) | 61.31 (13.80) | <0.001 |
| <65 years | 6213 (73.4) | 5215 (74.2) | 998 (69.6) | <0.001 | 769 (74.9) | 229 (56.3) | <0.001 |
| ≥65 years | 2253 (26.6) | 1817 (25.8) | 436 (30.4) | 258 (25.1) | 178 (43.7) | ||
| Sex, | |||||||
| Male | 4332 (51.2) | 3461 (49.2) | 871 (60.7) | <0.001 | 661 (64.4) | 210 (51.6) | <0.001 |
| Female | 4134 (48.8) | 3571 (50.8) | 563 (39.3) | 366 (35.6) | 197 (48.4) | ||
| BMI, mean (SD) | 22.89 (3.46) | 23.57 (3.06) | 19.55 (3.39) | <0.001 | 19.99 (3.43) | 18.43 (3.01) | <0.001 |
| <18.5 | 767 (9.1) | 0 (0.0) | 767 (53.5) | <0.001 | 497 (48.4) | 270 (66.3) | <0.001 |
| 18.5–23.9 | 4636 (54.8) | 4141 (58.9) | 495 (34.5) | 381 (37.1) | 114 (28.0) | ||
| 24–27.9 | 2461 (29.1) | 2312 (32.9) | 149 (10.4) | 127 (12.4) | 22 (5.4) | ||
| ≥28 | 602 (7.1) | 579 (8.2) | 23 (1.6) | 22 (2.1) | 1 (0.2) | ||
| TNM, | |||||||
| I | 1260 (14.9) | 1136 (16.2) | 124(8.6) | <0.001 | 98 (9.5) | 26 (6.4) | 0.13 |
| II | 2050 (24.2) | 1777 (25.3) | 273(19.0) | 198 (19.3) | 75 (18.4) | ||
| III | 2937 (34.7) | 2388 (34.0) | 549(38.3) | 396 (38.6) | 153 (37.6) | ||
| IV | 2219 (26.2) | 1731 (24.6) | 488(34.0) | 335 (32.6) | 153 (37.6) | ||
| Smoke, | |||||||
| No | 5114 (60.4) | 4361 (62.0) | 753 (52.5) | <0.001 | 504 (49.1) | 249 (61.2) | <0.001 |
| Yes | 3352 (39.6) | 2671 (38.0) | 681 (47.5) | 523 (50.9) | 158 (38.8) | ||
| Primary tumour, | |||||||
| Oesophagus cancer | 453 (5.4) | 324 (4.6) | 129 (9.0) | 93 (9.1) | 36 (8.8) | ||
| Lung cancer | 1864 (22.0) | 1585 (22.5) | 279 (19.5) | 203 (19.8) | 76 (18.7) | ||
| Pancreatic cancer | 100 (1.2) | 55 (0.8) | 45 (3.1) | 30 (2.9) | 15 (3.7) | ||
| Gastric cancer | 968 (11.4) | 656 (9.3) | 312 (21.8) | 212 (20.6) | 100 (24.6) | ||
| Colorectal cancer | 1514 (17.9) | 1186 (16.9) | 328 (22.9) | 231 (22.5) | 97 (23.8) | ||
| Nasopharynx cancer | 950 (11.2) | 852 (12.1) | 98 (6.8) | 79 (7.7) | 19 (4.7) | ||
| Breast cancer | 1485 (17.5) | 1423 (20.2) | 62 (4.3) | 48 (4.7) | 14 (3.4) | ||
| Cervical cancer | 349 (4.1) | 314 (4.5) | 35 (2.4) | 23 (2.2) | 12 (2.9) | ||
| Ovarian cancer | 205 (2.4) | 157 (2.2) | 48 (3.3) | 29 (2.8) | 19 (4.7) | ||
| Liver cancer | 191 (2.3) | 157 (2.2) | 34 (2.4) | 27 (2.6) | 7 (1.7) | ||
| Other cancer | 387 (4.6) | 323 (4.6) | 64 (4.5) | 52 (5.1) | 12 (2.9) | ||
| Alcohol, | |||||||
| No | 6898 (81.5) | 5810 (82.6) | 1088 (75.9) | <0.001 | 745 (72.5) | 343 (84.3) | <0.001 |
| Yes | 1568 (18.5) | 1222 (17.4) | 346 (24.1) | 282 (27.5) | 64 (15.7) | ||
| Nutrition support, | |||||||
| No | 7105 (83.9) | 6051(86.0) | 1054 (73.5) | <0.001 | 791 (77.0) | 263 (64.6) | <0.001 |
| Yes | 1361 (16.1) | 981(14.0) | 380 (26.5) | 236 (23.0) | 144 (35.4) | ||
| Anorexia, | |||||||
| No | 7378 (87.1) | 6300 (89.6) | 1078 (75.2) | <0.001 | 821 (79.9) | 257 (63.1) | <0.001 |
| Yes | 1088 (12.9) | 732 (10.4) | 356 (24.8) | 206 (20.1) | 150 (36.9) | ||
| NRS‐2002, n (%) | |||||||
| <3 | 6258 (73.9) | 6096 (86.7) | 162 (11.3) | <0.001 | 132 (12.9) | 30 (7.4) | 0.004 |
| ≥3 | 2208 (26.1) | 936 (13.3) | 1272 (88.7) | 895(87.1) | 377 (92.6) | ||
| PG‐SGA, | |||||||
| 0–3 | 4302 (50.8) | 4103 (58.3) | 199 (13.9) | <0.001 | 168 (16.4) | 31 (7.6) | <0.001 |
| 4–8 | 2593 (30.6) | 2093 (29.8) | 500 (34.9) | 396 (38.6) | 104 (25.6) | ||
| ≥9 | 1571 (18.6) | 836 (11.9) | 735 (51.3) | 463 (45.1) | 272 (66.8) | ||
| KPS, mean (SD) | 87.14 (12.68) | 88.14 (11.65) | 82.26 (15.98) | <0.001 | 85.38 (12.52) | 74.37 (20.45) | <0.001 |
| Albumin (g/L), mean (SD) | 39.54 (10.49) | 39.89 (8.52) | 35.17 (7.89) | <0.001 | 38.85 (19.42) | 35.17 (7.89) | |
| ≥35 | 6879 (81.3) | 5922 (84.2) | 957 (66.7) | <0.001 | 742 (72.2) | 215 (52.8) | <0.001 |
| <35 | 1587 (18.7) | 1110 (15.8) | 477 (33.3) | 285 (27.8) | 192 (47.2) | ||
| NLR (mean (SD)) | 3.54 (4.05) | 3.37 (3.85) | 4.39 (4.82) | <0.001 | 3.86 (3.58) | 4.71 (3.82) | <0.001 |
| MAC (cm), Mean (SD) | 26.59 (3.54) | 27.08 (3.31) | 24.18 (3.67) | <0.001 | 24.75 (3.54) | 22.74 (3.62) | <0.001 |
| TSF (mm), Mean (SD) | 16.90 (8.01) | 17.78 (7.88) | 12.61 (7.19) | <0.001 | 13.26 (7.40) | 10.97 (6.37) | <0.001 |
| HGS, kg, Mean (SD) | 24.89 (10.47) | 25.24 (10.37) | 23.14 (10.80) | <0.001 | 27.52 (9.34) | 12.09 (4.49) | <0.001 |
| MAMC (cm), Mean (SD) | 20.84 (3.42) | 21.03 (3.42) | 19.90 (3.26) | <0.001 | 20.25 (3.22) | 19.02 (3.19) | <0.001 |
| CC (cm), Mean (SD) | 33.23 (3.90) | 33.72(3.68) | 30.84 (4.05) | <0.001 | 31.45 (3.94) | 29.29 (3.93) | <0.001 |
| ASMI (kg/m2), Mean (SD) | 6.81 (1.02) | 6.91(0.98) | 6.31 (1.09) | <0.001 | 6.48 (1.06) | 5.88 (1.03) | <0.001 |
ASMI, appendicular skeletal muscle index; BMI, body mass index; CC, calf circumference (left calf); HGS, hand grip strength; KPS, Karnofsky Performance Status; MAC, mid‐arm circumference; MAMC, mid‐arm muscle circumference; NLR, neutrophil‐to‐lymphocyte ratio; NRS‐2002, the Nutritional Risk Screening 2002; PG‐SGA, Patient‐Generated Subjective Global Assessment; SD, standard deviation; TSF, triceps skinfold thickness.
All of other cancers were solid neoplasms, including bladder cancer, prostate cancer, endometrial cancer, malignant brain tumour, gastric stromal tumour, and biliary tract cancer.
Figure 2Difference in hand grip strength between patients with or without cachexia in different cancers. Other cancers included were solid neoplasms, including bladder cancer, prostate cancer, malignant brain tumour, gastric stromal tumour, and biliary tract cancer.
Figure 3Determining cut‐off values of low hand grip strength based on sex‐specific (male and female) strata. Plot of standardized log‐rank statistics of hand grip strength (left panels) and the Kaplan–Meier plot according to the cut point of hand grip strength (right panels). The optimal cut‐off value of hand grip strength in cachexia was 14.3 kg for female patients (P < 0.0001) and 19.87 kg for male patients (P < 0.0001).
Univariate and multivariate cox regression analysis of overall survival in cancer patients with cachexia.
| Variables | Univariate analysis |
| Multivariate analysis |
|
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age ≥65 vs. <65 | 1.550 (1.320–1.800) | <0.001 | 1.174 (0.995–1.386) | 0.0574 |
| Sex male vs. female | 0.681 (0.581–0.798) | <0.001 | 0.821 (0.668–1.010) | 0.0617 |
| TNM | ||||
| I | (Reference) | (Reference) | ||
| II | 1.420 (0.898–2.260) | 0.133 | 1.244 (0.783–1.978) | 0.008 |
| III | 2.593 (1.704–3.947) | <0.001 | 2.278 (1.494–3.472) | <0.001 |
| IV | 6.564 (4.337–9.934) | <0.001 | 5.684 (3.746–8.623) | <0.001 |
| BMI < 18.5 vs. ≥18.5 | 1.190 (1.020–1.380) | 0.0262 | 1.170 (1.001–1.367) | 0.0489 |
| NLR | 1.010 (1.000–1.010) | 0.0098 | 1.005 (0.998–1.013) | 0.1287 |
| Albumin (g/L), <35 vs. ≥35 | 2.240 (1.920–2.600) | <0.001 | 1.783 (1.523–2.088) | <0.001 |
| HGS low vs. high | 1.760 (1.510–2.060) | <0.001 | 1.491 (1.257–1.769) | <0.001 |
| Anorexia yes vs. no | 1.880 (1.600–2.200) | <0.001 | 1.435 (1.217–1.692) | <0.001 |
| Nutrition support yes vs. no | 1.200 (1.020–1.420) | 0.0293 | 1.158 (0.977–1.371) | 0.0902 |
| Alcohol yes vs. no | 1.270 (1.070–1.500) | 0.0056 | 1.162 (0.958–1.411) | 0.1278 |
| Smoke yes vs. no | 1.300 (1.120–1.510) | <0.001 | 1.135 (0.930–1.385) | 0.2122 |
BMI, body mass index; HGS, hand grip strength; HR, hazard ratio; NLR, neutrophil‐to‐lymphocyte ratio; 95% CI, 95% confidence interval.
Nutrition support include enteral nutrition and parenteral nutrition.
Figure 4The Kaplan–Meier curves of hand grip strength and 1 year survival in cancer patients with cachexia. (A) The association of low HGS and 1 year survival in all cancer patients with cachexia; (B,C) The association of low HGS and ‐year survival in male and female cancer patients with cachexia. (D–F) The association of low HGS and 1 year survival in different system cancer cachexia. Digestive system cancers include oesophageal cancer, colorectal cancer, gastric cancer, liver cancer, and pancreatic cancer; respiratory system cancer include lung cancer and nasopharynx cancer; other cancer include breast cancer, ovarian cancer, cervical cancer, bladder cancer, prostate cancer, endometrial cancer, malignant brain tumour, gastric stromal tumour and biliary tract cancer; HGS, hand grip strength.
Figure 5The interaction analysis of low hand grip strength and other factors in cancer patients with cachexia. BMI, body mass index; HGS, hand grip strength; NLR, neutrophil‐to‐lymphocyte ratio. All of hazard ratios abovementioned were adjusted by the factors that were significant in the univariate Cox analysis. Nutrition support includes enteral nutrition and parenteral nutrition. The optimal cut‐off value of NLR in cachexia was 3.48 (P < 0.001).
Figure 6The Kaplan–Meier curves of low hand grip strength and NLR and albumin interaction in cancer patients with cachexia. (A) The combined effect of low hand grip strength and high NLR on overall survival of cancer patients with cachexia. (B) The combined effect of low hand grip strength and low albumin on overall survival of cancer patients with cachexia. HGS, hand grip strength; NLR, neutrophil‐to‐lymphocyte ratio.